CARTA PROGRAM
Nationally produced CAR-T therapy, in conjunction with the Hospital de Clínicas.
CARTA is a joint initiative between Aviv Therapeutics and the Hospital de Clínicas, the university hospital of the Universidad de la República, to develop and produce CAR-T therapy within the country. Its goal is for patients to access one of the most advanced treatments in hematologic oncology without leaving Uruguay.
The program is supported by the Hematology Chair of the Faculty of Medicine and by the capabilities of the National Institute of Donation and Transplant (INDT), based in the hospital itself.
PRIMERA INDICACIÓN
Linfoma Difuso de Células Grandes B
PRIMEROS PACIENTES
2026-2027
SEDE
Hospital de Clínicas, UdelaR
PRIORIDAD
Acceso y continuidad
Nationally produced CAR-T therapy, in conjunction with the Hospital de Clínicas.
CARTA is a joint initiative between Aviv Therapeutics and the Hospital de Clínicas, the university hospital of the Universidad de la República, to develop and produce CAR-T therapy within the country. Its goal is for patients to access one of the most advanced treatments in hematologic oncology without leaving Uruguay.
The program is supported by the Hematology Chair of the Faculty of Medicine and by the capabilities of the National Institute of Donation and Transplant (INDT), based in the hospital itself.
PUNTO DE ATENCIÓN
Dentro del hospital
CALIDAD
Estándares GMP
PLANTA
CEPROTEA
ACCESO
A costo mucho menor
CARTA PROGRAM
Nationally produced CAR-T therapy, in conjunction with the Hospital de Clínicas.
CARTA is a joint initiative between Aviv Therapeutics and the Hospital de Clínicas, the university hospital of the Universidad de la República, to develop and produce CAR-T therapy within the country. Its goal is for patients to access one of the most advanced treatments in hematologic oncology without leaving Uruguay.
The program is supported by the Hematology Chair of the Faculty of Medicine and by the capabilities of the National Institute of Donation and Transplant (INDT), based in the hospital itself.
CASOS LDGCB · AÑO
11.650
CANDIDATOS · AÑO
3.000+
ACCESO EFECTIVO
<1%
DISPONIBILIDAD